僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Denosumab （anti-RANK ligand） （AMG-162, Prolia, Xgeva） is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL （143–317） to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.